FDA Grants MET Inhibitor Tepotinib Accelerated Approval for NSCLC
The US Food and Drug Administration has granted accelerated approval for tepotinib for the treatment of adults with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations. FDA Approvals